Study Title

claritypharmaceuticals

64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer.

Study Details

Description:

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.

Contacts:

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

Inclusion
  • • Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy
  • • Negative or equivocal findings for PC
  • • Adequate liver function
  • • Estimated Glomerular Filtration Rate of 30 mL/min or higher.
  • • Suspected recurrence of prostate cancer (PC) based on rising Prostate specific antigen (PSA) after definitive therapy
Exclusion
  • •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
  • • Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468